BACKGROUND: The objectives of this study were to examine the patterns of use for adjuvant therapy and the changes in surgical practice for patients with early stage breast cancer and to describe how recent large clinical trial results impacted the patterns of care at The University of Texas M. D. Anderson Cancer Center (MDACC). METHODS: The study included 5486 women who were diagnosed with stage I through IIIA breast cancer between 1997 and 2004 and received their treatment at MDACC. A chi-square trend test and multivariate logistic regression model were used to assess changes in treatment patterns over time. RESULTS: Among lymph node-positive patients, the use of anthracycline plus taxane chemotherapy increased from 17% in 1997 to 81% in 2004 (P < .001). Meanwhile, the use of anthracyclines without taxanes dropped from 76% to 20% (P < .001) between 1997 and 2000. For postmenopausal patients who received endocrine therapy, the use of tamoxifen was replaced increasingly by the use of aromatase inhibitors (from 100% on tamoxifen in 1997 to 14% in 2004; P < .001). The percentage of women who underwent initial sentinel lymph node biopsy increased significantly during the period from 1997 to 2004 (from 1.8% to 69.7%, respectively, among patients who underwent mastectomy; and from 18.1% to 87.1%, respectively, among patients who underwent breast-conserving surgery; P < .001). CONCLUSIONS: The results from this study suggested that key findings from adjuvant therapy and surgical procedures from large clinical trials often prompt immediate changes in the patient care practices of research hospitals like MDACC.
BACKGROUND: The objectives of this study were to examine the patterns of use for adjuvant therapy and the changes in surgical practice for patients with early stage breast cancer and to describe how recent large clinical trial results impacted the patterns of care at The University of Texas M. D. Anderson Cancer Center (MDACC). METHODS: The study included 5486 women who were diagnosed with stage I through IIIA breast cancer between 1997 and 2004 and received their treatment at MDACC. A chi-square trend test and multivariate logistic regression model were used to assess changes in treatment patterns over time. RESULTS: Among lymph node-positive patients, the use of anthracycline plus taxane chemotherapy increased from 17% in 1997 to 81% in 2004 (P < .001). Meanwhile, the use of anthracyclines without taxanes dropped from 76% to 20% (P < .001) between 1997 and 2000. For postmenopausal patients who received endocrine therapy, the use of tamoxifen was replaced increasingly by the use of aromatase inhibitors (from 100% on tamoxifen in 1997 to 14% in 2004; P < .001). The percentage of women who underwent initial sentinel lymph node biopsy increased significantly during the period from 1997 to 2004 (from 1.8% to 69.7%, respectively, among patients who underwent mastectomy; and from 18.1% to 87.1%, respectively, among patients who underwent breast-conserving surgery; P < .001). CONCLUSIONS: The results from this study suggested that key findings from adjuvant therapy and surgical procedures from large clinical trials often prompt immediate changes in the patient care practices of research hospitals like MDACC.
Authors: Gary H Lyman; Armando E Giuliano; Mark R Somerfield; Al B Benson; Diane C Bodurka; Harold J Burstein; Alistair J Cochran; Hiram S Cody; Stephen B Edge; Sharon Galper; James A Hayman; Theodore Y Kim; Cheryl L Perkins; Donald A Podoloff; Visa Haran Sivasubramaniam; Roderick R Turner; Richard Wahl; Donald L Weaver; Antonio C Wolff; Eric P Winer Journal: J Clin Oncol Date: 2005-09-12 Impact factor: 44.544
Authors: Steven D Heys; Andrew W Hutcheon; Tarun K Sarkar; Keith N Ogston; Iain D Miller; Simon Payne; Ian Smith; Leslie G Walker; Oleg Eremin Journal: Clin Breast Cancer Date: 2002-10 Impact factor: 3.225
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Brian D Badgwell; Stephen P Povoski; Shahab F Abdessalam; Donn C Young; William B Farrar; Michael J Walker; Lisa D Yee; Emmanuel E Zervos; William E Carson; William E Burak Journal: Ann Surg Oncol Date: 2003-05 Impact factor: 5.344
Authors: Amy Y Chen; Michael T Halpern; Nicole M Schrag; Andrew Stewart; Marilyn Leitch; Elizabeth Ward Journal: J Natl Cancer Inst Date: 2008-03-25 Impact factor: 13.506
Authors: I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544
Authors: Pamela R Soulos; James B Yu; Kenneth B Roberts; Ann C Raldow; Jeph Herrin; Jessica B Long; Cary P Gross Journal: J Clin Oncol Date: 2012-03-05 Impact factor: 44.544
Authors: Mariana Chavez-MacGregor; Elizabeth A Mittendorf; Christina A Clarke; Daphne Y Lichtensztajn; Kelly K Hunt; Sharon H Giordano Journal: Oncologist Date: 2017-06-07
Authors: Cameron B Haas; Erin J Aiello Bowles; Janie M Lee; Jennifer Specht; Diana S M Buist Journal: Cancer Causes Control Date: 2022-07-07 Impact factor: 2.532